J. C. Tapia

Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study

S. Salah, R. Kanesvaran, P. Giannatempo, 2024, Scientific reports.

Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.

O. Fiala, S. Salah, J. Bellmunt, 2023, Clinical and experimental medicine.